Oh the Places You’ll Go (with 1 billion regressions an hour) explores the partnership with Alnylam to access and understand the data from the UK Biobank project.
Click the image below to view the full video:
Oh the Places You’ll Go (with 1 billion regressions an hour) explores the partnership with Alnylam to access and understand the data from the UK Biobank project.
Click the image below to view the full video:
Life science researchers and drug discovery scientists today work in what, in my view, will be remembered in the future as the beginning of a “golden era” where the power of genetic information is connected to a wide range of other healthcare and lifestyle data to support better understanding of
25th October 2022: Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline. Using Paradigm4’s cloud-based scientific analytics platform and data from the UK Biobank, Alnylam has identified
Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.
